JP6268173B2 - 抗Ｓｉｇｌｅｃ−１５抗体 - Google Patents

抗Ｓｉｇｌｅｃ−１５抗体 Download PDF

Info

Publication number
JP6268173B2
JP6268173B2 JP2015521915A JP2015521915A JP6268173B2 JP 6268173 B2 JP6268173 B2 JP 6268173B2 JP 2015521915 A JP2015521915 A JP 2015521915A JP 2015521915 A JP2015521915 A JP 2015521915A JP 6268173 B2 JP6268173 B2 JP 6268173B2
Authority
JP
Japan
Prior art keywords
seq
antibody
siglec
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524256A5 (enExample
JP2015524256A (ja
Inventor
マシュー・スタイブル
ジル・ベルナール・トランブレ
トライアン・シュレア
アンナ・エヌ・モライティス
マリオ・フィリオン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JP2015524256A publication Critical patent/JP2015524256A/ja
Publication of JP2015524256A5 publication Critical patent/JP2015524256A5/ja
Application granted granted Critical
Publication of JP6268173B2 publication Critical patent/JP6268173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015521915A 2012-07-19 2013-07-17 抗Ｓｉｇｌｅｃ−１５抗体 Active JP6268173B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261673442P 2012-07-19 2012-07-19
US61/673,442 2012-07-19
US201361777049P 2013-03-12 2013-03-12
US61/777,049 2013-03-12
US201361810415P 2013-04-10 2013-04-10
US61/810,415 2013-04-10
PCT/CA2013/000646 WO2014012165A1 (en) 2012-07-19 2013-07-17 Anti-siglec-15 antibodies

Publications (3)

Publication Number Publication Date
JP2015524256A JP2015524256A (ja) 2015-08-24
JP2015524256A5 JP2015524256A5 (enExample) 2016-09-08
JP6268173B2 true JP6268173B2 (ja) 2018-01-24

Family

ID=49948128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521915A Active JP6268173B2 (ja) 2012-07-19 2013-07-17 抗Ｓｉｇｌｅｃ−１５抗体

Country Status (15)

Country Link
US (1) US9493562B2 (enExample)
EP (1) EP2875051B1 (enExample)
JP (1) JP6268173B2 (enExample)
KR (1) KR20150036274A (enExample)
CN (1) CN104507969A (enExample)
AU (1) AU2013293062A1 (enExample)
CA (2) CA2928851A1 (enExample)
EA (1) EA201590247A1 (enExample)
ES (1) ES2723885T3 (enExample)
HK (1) HK1210192A1 (enExample)
IL (1) IL236259A0 (enExample)
IN (1) IN2014KN02933A (enExample)
MX (1) MX2015000863A (enExample)
WO (1) WO2014012165A1 (enExample)
ZA (1) ZA201409358B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP3157562A4 (en) * 2014-06-18 2017-12-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
AU2017207082B2 (en) * 2016-01-12 2023-07-13 Eisai Randd Management Co., Ltd. Anti-Myl9 antibody
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN110035769A (zh) * 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
EP3538152A4 (en) * 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
WO2019114793A1 (zh) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
WO2020232243A2 (en) * 2019-05-14 2020-11-19 Froude Jeffrey W Antibodies to sudan and ebola virus
CN115551895A (zh) * 2020-03-05 2022-12-30 纪念斯隆凯特琳癌症中心 抗ccr8剂
CA3173201A1 (en) * 2020-03-27 2021-09-30 Mingjiu Chen Antibodies binding siglec15 and uses thereof
WO2022095934A1 (zh) * 2020-11-05 2022-05-12 上海津曼特生物科技有限公司 抗Siglec-15抗体及其在制备药物中的应用
WO2022179483A1 (zh) * 2021-02-23 2022-09-01 上海济煜医药科技有限公司 Siglec-15结合蛋白的制备及其用途
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112961214B (zh) * 2021-03-19 2022-08-02 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112979761B (zh) * 2021-03-19 2021-12-10 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CA3214281A1 (en) * 2021-03-19 2022-09-22 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
CN114591434B (zh) * 2021-04-30 2023-02-28 杭州邦顺制药有限公司 抗Siglec15抗体及其制备方法和用途
WO2022237819A1 (zh) * 2021-05-13 2022-11-17 信达生物制药(苏州)有限公司 抗Siglec-15抗体及其用途
CN114395042B (zh) * 2022-03-28 2022-06-10 北京科诺信诚科技有限公司 抗il-33人源化抗体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116804057A (zh) * 2022-11-22 2023-09-26 浙江博锐生物制药有限公司 抗Siglec-15抗体及其用途
CN119708217B (zh) * 2024-12-25 2025-11-25 深圳重链生物科技有限公司 抗链霉亲和素抗体及其相关应用

Family Cites Families (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4554162A (en) 1984-05-04 1985-11-19 Warner-Lambert Company CL-1724 Antibiotic compounds, their production and use
US4539203A (en) 1984-11-13 1985-09-03 Warner-Lambert Company CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US4837206A (en) 1987-04-29 1989-06-06 Bristol-Myers Company Esperamicin derivatives
LU87693A1 (fr) 1990-03-07 1991-10-08 Wurth Paul Sa Sonde de prise d'echantillons gazeux et de mesures thermiques dans un four a cuve
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5817303A (en) 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP2336168A1 (en) 1997-04-15 2011-06-22 Sankyo Company Limited Novel protein and method for producing the protein
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
AU2980199A (en) 1998-03-04 1999-09-20 Genencor International, Inc. Modified forms of pullulanase
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US7060433B1 (en) 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1200109A4 (en) 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
WO2001055391A2 (en) 2000-01-26 2001-08-02 Agensys, Inc 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
JP2004533803A (ja) 2000-09-08 2004-11-11 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ヒトにおいてインビボでペプチドをターゲティングするための組成物及び方法
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
CA2428140A1 (en) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
AU2002222747A1 (en) 2000-12-12 2002-06-24 Angiolab, Inc. Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
US7459539B2 (en) 2000-12-15 2008-12-02 Agensys, Inc. Antibody that binds zinc transporter protein 108P5H8
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JPWO2002064771A1 (ja) 2001-02-15 2004-06-17 持田製薬株式会社 活性化白血球に特異的な新規細胞接着分子
ES2389285T3 (es) 2001-03-28 2012-10-24 Helix Biomedix, Inc. Péptidos bioactivos cortos y procedimientos para su uso
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6967021B2 (en) 2001-04-27 2005-11-22 Trustees Of Tufts College Use of Galectin-3 to promote the re-epithelialization of wounds
DE60225545T2 (de) 2001-05-07 2009-04-02 National Research Council Of Canada, Ottawa Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen
JP2004529740A (ja) 2001-06-15 2004-09-30 ジョーンズ ホプキンズ シンガポール ピーティーイー リミテッド 生体機能繊維
EP2270052B8 (en) 2001-06-26 2018-05-02 Amgen Inc. Antibodies to OPGL
US7033991B2 (en) 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
DK1485707T3 (da) 2001-07-16 2009-05-11 Caprotec Bioanalytics Gmbh Indsamlingsforbindelser, samlinger deraf og fremgangsmåder til analyse af proteomet og komplekse sammensætninger
US20090075377A1 (en) 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
US7402664B2 (en) 2002-09-03 2008-07-22 Genencor International, Inc. Nucleic acids and expression vectors comprising carotenoid binding peptides
JP4120778B2 (ja) 2001-09-26 2008-07-16 国立大学法人 奈良先端科学技術大学院大学 骨代謝異常疾患マーカー及びその利用
US20050107588A1 (en) 2001-11-13 2005-05-19 Duggan Brendan M. Receptors and membrane-associated proteins
JP2003210166A (ja) 2001-11-16 2003-07-29 Sanyo Chem Ind Ltd 変温動物由来細胞の細胞接着基材
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242618A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Stratification
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20080242837A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20080318871A1 (en) 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20080194489A1 (en) 2001-12-21 2008-08-14 Khan Nisar A Treatment of iatrogenic disease
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
CA2471762C (en) 2002-01-09 2010-08-17 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7514407B2 (en) 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
US8298606B2 (en) 2002-03-08 2012-10-30 The Regents Of The University Of California Methods and compositions for stabilizing the myocardium
WO2003080671A1 (en) 2002-03-21 2003-10-02 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US20040102608A1 (en) 2002-05-13 2004-05-27 Cornell Research Foundation, Inc. Multiblock copolymers having improved mechanical properties
US20040115132A1 (en) 2002-05-17 2004-06-17 Young Mark J. Protein cages for the delivery of medical imaging and therapeutic agents
ATE500326T1 (de) 2002-06-06 2011-03-15 Oncotherapy Science Inc Gene und proteine mit bezug zu menschlichem kolonkrebs
JP2005535634A (ja) 2002-06-28 2005-11-24 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） Ｆｌｔ−１に対する抗体の骨粗鬆症の処置のための使用
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AU2003275473A1 (en) 2002-10-08 2004-05-04 Genencor International, Inc. Phenolic binding peptides
US7572894B2 (en) 2002-11-01 2009-08-11 Trustees Of Tufts College Templated native silk smectic gels
DK2317317T3 (en) 2002-12-03 2015-03-02 Univ North Carolina State Prion protein ligands, as well as methods of use thereof
JP2004189848A (ja) 2002-12-10 2004-07-08 Giken:Kk 炭化処理方法および炭化処理システム
WO2004064972A2 (en) 2003-01-16 2004-08-05 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
JP3906924B2 (ja) 2003-02-28 2007-04-18 独立行政法人農業生物資源研究所 絹タンパクから細胞生育ペプチドの抽出と利用
US7547512B2 (en) 2003-03-24 2009-06-16 The University Of Hong Kong High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
CN102021147B (zh) 2003-03-24 2016-08-03 港大科桥有限公司 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP1613796B1 (en) 2003-04-10 2017-03-22 Tufts University Concentrated aqueous silk fibroin solution and use thereof
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
JP3915983B2 (ja) 2003-05-27 2007-05-16 ゼライス株式会社 プロテアーゼ、このプロテアーゼをコードするｄｎａ、プロテアーゼの製造方法
AU2004246909B2 (en) 2003-06-19 2010-08-19 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
FR2860237B1 (fr) 2003-09-30 2006-03-10 Centre Nat Rech Scient Polypeptide d'interaction comprenant un motif heptapeptidique et un domaine de penetration cellulaire
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
US20090226374A1 (en) 2003-10-27 2009-09-10 Health Aide, Inc. Anaphylatoxins for detecting clinical conditions
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
US20090227505A1 (en) 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
US20090169520A1 (en) 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
EP1718753A4 (en) 2004-01-28 2009-01-21 Univ Johns Hopkins Methods for making and using molecular switches involving circular permutation
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
WO2005080432A2 (en) 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
WO2005081628A2 (en) 2004-03-01 2005-09-09 Peptera Pharmaceutical Ltd. Casein derived peptides and therapeutic uses thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US7192739B2 (en) 2004-03-30 2007-03-20 President And Fellows Of Harvard College Ligand-dependent protein splicing
JP2008506359A (ja) 2004-04-08 2008-03-06 サンガモ バイオサイエンシズ インコーポレイテッド ジンクフィンガータンパク質による神経因性疼痛の処置
US7189697B2 (en) 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
US7603239B2 (en) 2004-05-05 2009-10-13 Massachusetts Institute Of Technology Methods and systems for generating peptides
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
CA2573293A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
EP1786451A4 (en) 2004-08-06 2009-07-22 Sopherion Therapeutics Inc ANTIANGIOGENIC PEPTIDES AND METHOD FOR THEIR USE
JP2006068378A (ja) 2004-09-03 2006-03-16 Terumo Corp 血管内留置物
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
WO2006044614A2 (en) 2004-10-14 2006-04-27 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2116603A3 (en) 2004-11-12 2010-02-17 The University Of British Columbia Antimicrobial peptides
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
US8022040B2 (en) 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CA2590751A1 (en) 2004-12-13 2006-06-22 Roy Rabindranauth Sooknanan Polynucleotides and polypeptide sequences involved in the process of bone remodeling
WO2006078746A2 (en) 2005-01-19 2006-07-27 Mathew Mark Zuckerman Method, compositions and classification for tumor diagnostics and treatment
JP2008528668A (ja) 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
CA2597191C (en) 2005-02-09 2014-04-01 Helix Biomedix Inc. Antimicrobial hexapeptides
US8551774B2 (en) 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US20090180958A1 (en) 2005-04-26 2009-07-16 Karyon-Ctt Ltd. Diagnostic and therapeutic agents
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
US8227573B2 (en) 2005-05-20 2012-07-24 University Of Kentucky Research Foundation Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants
US7528232B2 (en) 2005-05-20 2009-05-05 The University Of Kentucky Research Foundation Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in crop plants
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
JP4604184B2 (ja) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
EP1928897A4 (en) 2005-08-11 2009-03-18 Scripps Research Inst ZINCFINGER BINDING DOMAIN FOR CNN
EP1945656A2 (en) 2005-08-22 2008-07-23 Genencor International, Inc. Nanocomposites of repeat sequence proteins and phyllosilicate clays and their preparation
US8486411B2 (en) 2005-08-30 2013-07-16 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
AU2006293421A1 (en) 2005-09-22 2007-03-29 Yeda Research And Development Co. Ltd., At The Weizmann Institute Of Science Diastereomeric peptides for modulating T cell immunity
EA016186B1 (ru) 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
EP1941275B1 (en) 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2007043059A1 (en) 2005-10-13 2007-04-19 Biocon Limited Process for the preparation of insulin conjugates.
US7575876B2 (en) 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
CA2628708C (en) 2005-11-08 2011-11-29 Tohoku University Method of quantifying membrane protein by using mass spectrometer
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007145659A1 (en) 2005-11-10 2007-12-21 The Regents Of The University Of California Synthetic ldl as targeted drug delivery vehicle
WO2007062422A2 (en) 2005-11-28 2007-05-31 The Scripps Research Institute Zinc finger binding domains for tnn
GB0524313D0 (en) 2005-11-29 2006-01-04 Imp College Innovations Ltd Particles
KR100838715B1 (ko) 2005-12-16 2008-06-16 국립암센터 트란스글루타미나제를 억제하는 펩타이드
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US20090246283A1 (en) 2006-02-23 2009-10-01 Danisco Us Inc., Genecor Division Repeat Sequence Protein Polymer Nanoparticles Optionally Containing Active Agents and Their Preparation
US7501557B1 (en) 2006-02-28 2009-03-10 University Of Kentucky Research Foundation Method utilizing the tobacco phylloplanin promoter for expression of nucleic acids as gene products directed to aerial surfaces of plants
EP1992220B1 (en) 2006-02-28 2013-05-22 Japan Science and Technology Agency Plant having reduced lignin and cellulose contents without reducing glucan content, method of producing the same and utilization thereof
WO2007104062A2 (en) 2006-03-09 2007-09-13 The Board Of Regents Of The University Of Texas System Compositions and methods based on peptide binding profiling
CN101405384B (zh) 2006-03-17 2013-12-04 三洋化成工业株式会社 细胞培养用载体以及制造方法和应用
WO2007111952A2 (en) 2006-03-22 2007-10-04 The Scripps Research Institute Method of preparing glycopeptides
CA2646406A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-igf-ir antibodies and uses thereof
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8187833B2 (en) 2006-05-08 2012-05-29 Adaerata Limited Partnership Chimeric PCSK9 proteins, cells comprising same, and assays using same
FR2900826B1 (fr) 2006-05-12 2008-08-15 Soc Extraction Principes Actif Utilisation de peptides en tant que principes actifs amincissants.
WO2007147014A2 (en) 2006-06-13 2007-12-21 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
JP2009542228A (ja) 2006-07-05 2009-12-03 ザ スクリプス リサーチ インスティテュート 定方向進化による触媒作用のために最適化されたキメラジンクフィンガーリコンビナーゼ
CN101490550A (zh) 2006-07-08 2009-07-22 肯塔基大学研究基金会 肺癌诊断分析
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP2008094822A (ja) 2006-09-15 2008-04-24 Univ Of Tokyo セルロース結合性ペプチドおよびその製造方法
EP2097536B1 (en) 2006-10-31 2014-07-16 MUSC Foundation For Research Development Systems for in vivo measurement of interstitial biological activity, processes and/or compositions
US20100159486A1 (en) 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
ITTO20060852A1 (it) 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US9175422B2 (en) 2007-01-22 2015-11-03 The United States Of America As Represented By The Secretary Of The Army Polymer-micelle complex as an aid to electrospinning
EP2129682A4 (en) 2007-01-29 2011-07-20 Procell Therapeutics Inc NOVEL DOMAINS OF MACROMOLECULE TRANSDUCTION AND METHODS OF IDENTIFICATION AND USES THEREOF
PE20081795A1 (es) 2007-02-16 2009-01-08 Genentech Inc Moduladores de htra1-pdz y htra3-pdz
US9415084B2 (en) 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
WO2008112904A2 (en) 2007-03-15 2008-09-18 Invitrogen Corporation Adhering surfaces
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
JP2008263955A (ja) 2007-03-29 2008-11-06 Sanyo Chem Ind Ltd 無血清培地
US20080306001A1 (en) 2007-04-04 2008-12-11 Anzelika Liik Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
WO2008137122A2 (en) 2007-05-04 2008-11-13 Shiloh Laoratories, Inc. Inducing premature senescence to stabilize stem cell feeder layer cells
US8097581B2 (en) 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
WO2008151146A2 (en) 2007-06-01 2008-12-11 Digitab, Inc. Peptide arrays and methods of use
EP2009023A1 (en) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
CN101778891B (zh) 2007-06-13 2013-01-16 Fmc有限公司 涂覆藻酸盐的含多糖凝胶泡沫复合物,其制备方法及其应用
US20090017460A1 (en) 2007-06-15 2009-01-15 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
EP3443976A1 (en) 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
WO2009020101A1 (ja) 2007-08-06 2009-02-12 University Of Tsukuba 花の形態が改変された植物体の生産方法
WO2009023125A1 (en) 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2009032158A2 (en) 2007-08-28 2009-03-12 Fmc Corporation, Inc. Delayed self-gelling alginate systems and uses thereof
JP5295242B2 (ja) 2007-09-04 2013-09-18 プロセル セラピューティックス インコーポレーティッド 細胞透過性Ｎｍ２３組換えタンパク質、これをコードするポリヌクレオチド及びこれを有効成分として含有する癌転移抑制用組成物
KR100887266B1 (ko) 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
JP5000439B2 (ja) 2007-09-19 2012-08-15 三洋化成工業株式会社 細胞培養用担体
WO2009038756A2 (en) 2007-09-20 2009-03-26 The J. David Gladstone Institutes Long interspersed nuclear element polypeptide compositions and methods of use thereof
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2206727B1 (en) 2007-10-11 2015-04-01 Daiichi Sankyo Company, Limited ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
GB0720156D0 (en) 2007-10-15 2007-11-28 Univ Nottingham Trent Breast cancer associated antigen
KR101668803B1 (ko) 2007-10-29 2016-10-24 헬릭스 바이오메딕스, 인코포레이티드 보호용 피부 관리 테트라펩티드
JP6039879B2 (ja) 2007-11-05 2016-12-07 ノルディック・ビオサイエンス・エー／エスＮｏｒｄｉｃ Ｂｉｏｓｃｉｅｎｃｅ Ａ／Ｓ Ｃｖｄリスク評価のための生化学マーカー
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
EP2209892A2 (en) 2007-11-06 2010-07-28 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
EP2217614A4 (en) 2007-11-07 2011-12-07 Dynamic Microbials Ltd ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND APPLICATIONS THEREOF
WO2009061890A1 (en) 2007-11-08 2009-05-14 St. Jude Children's Research Hospital Methods and compositions for the diagnosis, prognosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia
MX2010005244A (es) 2007-11-12 2010-10-25 Theraclone Sciences Inc Composiciones y métodos para la terapia y el diagnóstico de influenza.
FR2925500B1 (fr) 2007-12-21 2011-05-06 Vincience Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
FR2925501B1 (fr) 2007-12-21 2012-12-14 Vincience Peptide activateur de la synthese des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
JP2011514160A (ja) 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物
US20090298707A1 (en) 2008-03-18 2009-12-03 The Regents Of The University Of California Sparse matrix system and method for identification of specific ligands or targets
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20090281038A1 (en) 2008-05-09 2009-11-12 University Of Kentucky Research Foundation Phylloplanins Inhibition of Microbial Growth on Organic Materials
KR20110016867A (ko) 2008-05-16 2011-02-18 주식회사 프로셀제약 세포투과성 ｐ２７ 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
BRPI0914602A2 (pt) 2008-07-04 2015-12-15 Basf Plant Science Gmbh método para intensificar características relacionadas a rendimento em plantas em relação a plantas de controle, e para a produção de uma planta transgênica, molécula de ácido nucleico isolada, polipeptídeo isolado, construção, usos de uma construção e de um ácido nucleico, planta, partes de uma planta ou célula de planta, partes colhíveis de uma plantas ,e , produtos.
ES2589852T3 (es) 2008-09-17 2016-11-16 Xencor Inc. Anticuerpo específico para IgE
JP5299956B2 (ja) 2008-09-29 2013-09-25 国立大学法人東北大学 質量分析装置を用いた代謝酵素群の一斉タンパク質定量に用いるペプチド
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
PT2403878T (pt) 2009-03-05 2017-09-01 Squibb & Sons Llc Anticorpos completamente humanos específicos a cadm1
MX343049B (es) 2009-04-09 2016-10-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
RU2568051C2 (ru) 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. АНТИТЕЛА К ErbB3
EP2625205A2 (en) 2010-10-05 2013-08-14 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
CN104334722A (zh) 2012-03-30 2015-02-04 第一三共株式会社 具有修饰的cdr的抗-涎免凝集素15抗体
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15

Also Published As

Publication number Publication date
ES2723885T3 (es) 2019-09-03
CA2876517A1 (en) 2014-01-23
IN2014KN02933A (enExample) 2015-05-08
MX2015000863A (es) 2016-05-05
EP2875051B1 (en) 2019-02-20
AU2013293062A1 (en) 2014-07-24
WO2014012165A1 (en) 2014-01-23
JP2015524256A (ja) 2015-08-24
KR20150036274A (ko) 2015-04-07
HK1210192A1 (en) 2016-04-15
ZA201409358B (en) 2015-12-23
CN104507969A (zh) 2015-04-08
CA2876517C (en) 2019-01-08
CA2928851A1 (en) 2014-01-23
US9493562B2 (en) 2016-11-15
EP2875051A4 (en) 2016-06-08
EA201590247A1 (ru) 2015-10-30
US20150139982A1 (en) 2015-05-21
IL236259A0 (en) 2015-02-26
EP2875051A1 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
JP6268173B2 (ja) 抗Ｓｉｇｌｅｃ−１５抗体
US9617337B2 (en) Siglec-15 antibodies in treating bone loss-related disease
CA2960950C (en) Treatment of fibrodysplasia ossificans progressiva
JP6931609B2 (ja) 抗Ａｘｌアンタゴニスト抗体
DK2407486T3 (en) Antagonist antibodies to GDF-8 and uses in the treatment of ALS and other GDF-8-associated disorders
JP5816188B2 (ja) 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用
KR20190098255A (ko) 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
KR20200016899A (ko) 활성화가능 항-pdl1 항체, 및 이의 이용 방법
US12180285B2 (en) Antibodies to galectin-3 and methods of use thereof
CN104321430A (zh) 新颖的抗-siglec-15抗体
TW201726738A (zh) 對asct2具專一性之結合分子及其用途
CN104334722A (zh) 具有修饰的cdr的抗-涎免凝集素15抗体
US20170129956A1 (en) Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
US12459993B2 (en) Anti-alpha-synuclein antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171225

R150 Certificate of patent or registration of utility model

Ref document number: 6268173

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250